Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial
Zhihao Lu, Zhangzhou Huang, X. Meng, Yun Fan, Tao Wu, Qingsong Pang, Feng Wang, Yanqiao Zhang, Shegan Gao, Tianshu Liu, Jin Zhou, Yong Fang, Ning Li, Wei Li, Guochun Cao, Shoubing Zhou, Na Li, Feng Ye, Yinghua Ji, Jingdong Zhang, Xuwei Cai, Jianping Xiong, Mingjun Zhang, Lixin Wan, Yanhong Gu, Hui Luo, Xiaotian Zhang, Jinglei Qu, Wenhui Yang, Jianzhong Cao, Xueqiang Zhu, Jiayan Chen, Tienan Yi, Yongli Gao, Jiangqiong Huang, Zhenhua Liu, Jun Wang, Fang Ma, Yan Luo, Xuelei Ma, Jianfei Fu, Shubo Ding, Yu Liu, Sa Xiao, Hai Zhu, Yi Zhu, Lin Shen, PANKU-Esophagus01 Investigators, Yueyin Pan, Shouguo Li and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance Izalontamab brengitecan significantly improved PFS and OS vs chemotherapy in patients with recurrent or metastatic ESCC whose disease had progressed after first-line treatment.
Here, we introduce Mendelnoulli, a longitudinal model that combines the age-dependent effects of polygenic and monogenic variation on health records, separating how much disease each individual accumulates overall from diseases to which they are prone.
S. M. Urbut, B. Truong, S. Khurshid and 6 more — medRxiv
The genomic data, symptom onsets, and plausible contact patterns strongly support a tightly linked outbreak cluster compatible with a single or very few zoonotic spillover events prior to embarkment followed by human-to-human transmission onboard.
Marion Koopmans, Samuel Cordey, Moussa Moïse Diagne and 57 more — Science
FRET, however, reveals a specific interaction only on endosomes, where a Gas inhibitor restricted to that compartment abolishes the sustained cAMP phase without affecting receptor internalization.
J. Pacheco, S. Saha, K. A. Pena and 2 more — bioRxiv